The game of baseball has been kept under dark clouds after Mark McGwire made a belated confession of steroid use amidst crocodile tears and disclaimers. But Bud Selig thinks that the baseball steroid era is now over, a fact suggested by test results.
Though McGwire’s confession was not able to impress the die-hard baseball fans, it saved officials and team members by putting an end to the baseball’s era of performance-enhancing drugs to offer a new start for the game.
That’s pretty much what Bud Selig said after the man who wouldn’t talk about the past to Congress finally spoke about it to Bob Costas. On the day of McGwire’s mea culpa, Selig said in a statement that in 2010, the use of steroids and amphetamines in baseball is “virtually nonexistent, as our testing results have shown.”
Two things: Either the commissioner of Major League Baseball pays no attention to the nonstop cat-and-mouse game still taking place between the International Olympic Committee and its world-class athletes, or he’s back to his old car-selling ways again.
If he ever really left them.
Otherwise, he would not have followed with this: “The so-called steroid era — a reference that is resented by the many players who played in that era and never touched the substances — is clearly a thing of the past, and Mark’s admission today is another step in the right direction.”
The steroid era might be a thing of the past in baseball. But performance-enhancing drugs are an ever-evolving industry, as the IOC and its testing agents long ago discovered. Simply stated, the cycle goes as follows: You design a testing program to detect all known performance-enhancing drugs. They design a new drug that escapes that detection. After a while, you get wise, develop even more encompassing detection. They take your test, and build a new PED that avoids that detection.
Selig remarked that the use of steroids and amphetamines is no more prevalent in the world of baseball.
The use of Avastin alone can be considered as an effective form of treatment when it comes to treating a subgroup of recurrent Grade 3 brain tumors in terms of delaying tumor progression, as per a retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance.
Avastin, known generically as bevacizumab, is the first approved therapy designed for inhibiting angiogenesis that is a process in which new blood vessels develop and transport important nutrients to a tumor.
Chamberlain said he expects that patients treated with the drug will have a marked improvement in their quality of life because the use of steroids, a common treatment that has significant side effects, can be greatly reduced or even eliminated.
“While treatment with Avastin does dramatically improve survival time, the time that patients have left is of better quality and less about living with the disease itself,” Chamberlain said. In this study, the patients, ages 24-60, received an infusion of bevacizumab every two weeks for an average of 14.5 cycles (range was two to 39 cycles). Fourteen (64 percent) patients showed a partial response to the medicine as shown on radiographic scans. Two patients had stable disease and six had progressive disease. Progression-free survival ranged from three to 18 months and survival for the entire group of patients was three to 19 months.
Bevacizumab has the potential of being the best palliative treatment, as per Marc Chamberlain, M.D., author of this study that was published in the April 15 edition of the journal Cancer and director of the Neuro-oncology Program at the SCCA and a professor of neurology and neurological surgery at the University Of Washington School Of Medicine.
Individuals suffering from mild, persistent asthma and being administered with twice-daily use of inhaled steroids are likely to make lesser use of inhalers or find it easy to switch to a new pill.
It was remarked by Stephen P. Peters, M.D., Ph.D., lead author and a professor of pediatrics, internal medicine-pulmonary and associate director of the Center for Human Genomics, that this is good news for asthmatic patients because it offers them more choices in terms of asthma management.
The study, involving 500 children and adults with mild asthma, was conducted by the American Lung Association’s Asthma Clinical Research Centers. Its goal was to determine if patients whose symptoms are well controlled on twice daily inhaled corticosteroid can “step down” their medication use. The results are reported in the May 17 issue of the New England Journal of Medicine.
Asthma is considered mild, but persistent, when symptoms occur more than two times a week or cause the patient to awaken during the night more than twice a month. The standard treatment for mild-persistent asthma is twice-daily use of an inhaled steroid to prevent symptoms. Patients may also take additional drugs such as the inhaler albuterol, known as “rescue” therapy, to treat symptoms. A majority of people with asthma have mild disease, according to Peters.
The study involved patients whose asthma was treated with twice-daily inhaled fluticasone propionate (Flovent Discus), a commonly prescribed synthetic steroid. This drug is designed to suppress inflammation within the airways that can cause narrowing.
It was further remarked by Peters that asthmatic patients treated with twice a day inhaled corticosteroid doses and seeking other options must talk to their doctors before finalizing a decision.
Bodybuilders and strength athletes making use of anabolic steroids for delivering dramatic on-field performances may end up destroying their kidney. This previously unrecognized finding was revealed by a paper presented at the American Society of Nephrology’s 42nd Annual Meeting and Scientific Exposition in San Diego, CA.
The paper indicated that habitual use of anabolic steroids can lead to severe health complications, including severe kidney dysfunction.
Reports of professional athletes who abuse anabolic steroids are increasingly common. Most people know that using steroids is not good for your health, but until now, their effects on the kidneys have not been known. Leal Herlitz, MD (Columbia University Medical Center) and her colleagues recently conducted the first study describing injury to the kidneys following long-term abuse of anabolic steroids. The investigators studied a group of 10 bodybuilders who used steroids for many years and developed protein leakage into the urine and severe reductions in kidney function. Kidney tests revealed that nine of the ten bodybuilders developed a condition called focal segmental glomerulosclerosis, a type of scarring within the kidneys. This disease typically occurs when the kidneys are overworked. The kidney damage in the bodybuilders has similarities to that seen in morbidly obese patients, but appears to be even more severe.
This study was conducted in the laboratory of Dr. Vivette D’Agati, MD at Columbia Univeristy Medical Center. The list of study co-authors included Glen Markowitz, MD, Joshua Schwimmer, MD, Michael Stokes, MD, Cheryl Kunis, MD, Vivette D’Agati, MD, (Columbia University Medical Center); Alton Farris, MD, and Robert Colvin, MD (Massachusetts General Hospital).
Surgical repair of massive or recurrent tears of the shoulder’s rotator cuff tendons can be improved with anabolic steroids, as per a research from the UNC’s School of Medicine.
The study was led by Dr. Spero Karas, assistant professor of orthopedic surgery in UNC’s School of Medicine and appeared in an issue of the American Journal of Sports Medicine.
Anabolic steroids benefit millions of people a year, said Karas, including those with deficiencies in sex hormones and burn victims who need to build up their metabolism to repair musculoskeletal tissue. They also are FDA-approved for treating anemia for their ability to help the body rebuild blood.
As it’s widely known that anabolic steroids can build muscle mass and strength, Karas said he thought these properties might apply to shoulder tissue and that Banes’ bioartificial tendon might provide the appropriate model for testing.
“In this new study, supraspinatus tendon cells were harvested from my patients during rotator cuff surgery, isolated and then sent to Albert’s lab,” Karas said. “The cells were then grown in his culture media to coalesce and form this experimental tendon model, the bioartificial tendon.”
It was further remarked by Karas that there were significant improvements in the biomechanical properties of the bioartificial tendon matrices when they were initially treated with anabolic steroid and then mechanical load or strain.
A potential new treatment approach has been identified for treating severe asthma, as per a small study. The approach is focused up on blocking of a powerful immune system, which is present in large amounts in patients with the severe form of asthma.
It is believed that one out of every ten asthmatics suffers from severe asthma that frequently requires progressively higher doses of steroidsfor controlling symptoms.
Included in the study were 26 healthy people, 67 mild asthmatics, and 51 severe asthmatics. Bronchialfluid and lung tissue samples were taken from the participants to discover their levels of TNF alpha.
Levels were significantly higher in those with severe disease and concentrated in one particular type of immune cell (mast cells) which are recognised components of the inflammatory reaction in asthma.
TNF alpha levels were low and similar in those with no asthma or who only had mild symptoms.
This suggests that the high levels of TNF alpha in severe disease are characteristic of more chronic disease that is resistant to steroid treatment, rather than a feature of the disease itself, say the authors.
The authors caution that that more research is required in this field before the approach can be recommended at any stage but also said that this approach is a potentially new avenue of treatment for severe asthma.
Injecting a corticosteroid, triamcinolone, directly into the eye may slow the progression of proliferative diabetic retinopathy that is a complication of diabetes that results in blindness, according to researchers led by specialists at the Johns Hopkins Wilmer Eye Institute.
It was remarked that steroidsmay increase the risk of glaucoma and cataract and laser photocoagulation is the best treatment option till the time a new option is discovered, which has the good effects of steroids, minus the damage.
“Steroid treatment worked, but because of safety issues, cannot be recommended routinely at this time,” says Neil M. Bressler, the James P. Gills Professor of Ophthalmology and chief of the Retina Division of the Johns Hopkins Wilmer Eye Institute, chair of the government-sponsored Diabetic Retinopathy Clinical Research Network. “It is a condition that can be treated safely and effectively with lasers.”
The study, published in the December issue of the Archives of Ophthalmology, described and compared one of two treatments on 840 eyes from 693 men and women between July 2004 and May 2006. The subjects, about evenly divided between men and women with an average age of 63, had diabetic retinopathy with macular edema, a swelling of the central portion of the retina that’s caused by leakage of fluid.
Proliferative diabetic retinopathy is marked by the growth of new and unwanted blood vessels on the optic nerve in the back of the eye (which communicates information from the retina to the brain) or another area of the retina, the light-sensitive part of the eye. Despite advances in treating both diabetes and its complications, about 700,000 Americans have proliferative diabetic retinopathy and 63,000 new cases develop each year.
According to Bressler, lead author of the study, some evidences were found suggesting that steroids may possibly improve vision outcomes from diabetic macular edema (DME).
There is a possible link between a specific genetic variation and an increased risk for severe premenstrual depression, as per scientists at the University of North Carolina at Chapel Hill and the National Institute of Mental Health.
This psychiatric condition, known as a premenstrual dysphoric disorder, or PMDD, is considered to affect approximately 8 percent of women in their childbearing years and is featured by severe irritability and anxiety during second half of the menstrual cycle.
Compared to the control group, women with PMDD were significantly more likely to have the ESR1 gene variants, the study found.
“While these are preliminary findings that require replication in larger studies, we would argue that this may explain part of the variance among women in the susceptibility to developing this mood disorder,” Rubinow said. “Studies have shown that PMDD is characterized by abnormal sensitivity to reproductive steroidslike estrogen. As a receptor for the hormone that can trigger the onset of PMDD symptoms, ESR1 has clear physiologic relevance for this disorder.”
The authors acknowledge that as with other complex genetic disorders, the contribution to PMDD of polymorphisms in a single gene may not be large. In addition, they also noted that the findings may be telling us more about the control group.
Dr. David R. Rubinow, the study’s senior author and the Meymandi distinguished professor and chair of psychiatry at UNC School of Medicine, remarked that this study could help in obtaining important clues as to how some women suffer from mood changes while others do not besides finding the nature of that susceptibility.
Steroid treatment is not an effective option for providing relief to infants with a common and potentially serious viral lower respiratory infection called bronchiolitis, as per a new study co-authored by Dr. Joan Bregstein of the Morgan Stanley Children’s Hospital of NewYork-Presbyterian andColumbia University Medical Center.
The study suggested that steroids do not help in preventing hospitalization or improve respiratory symptoms for bronchiolitis that is believed to be the common cause of hospitalization among infants.
“Our study shows that treating bronchiolitis with steroids doesn’t work. We hope this study will resolve some of the uncertainty for physicians and families, as we move forward in developing better means of preventing and treating the infection,” says Dr. Bregstein, site principal investigator and emergency medicine pediatrician at Morgan Stanley Children’s Hospital of NewYork-Presbyterian and assistant clinical professor of pediatrics at Columbia University College of Physicians and Surgeons.
Current recommendations suggest that simple supportive care is the best available treatment for bronchiolitis. Researchers note that steroid-based medications still play an important role in other respiratory illnesses of childhood such as asthma and croup. They point out these medications are not the androgenic steroids sometimes abused by athletes, and that the side effects seen with long-term steroid use are not a risk in the short-course treatments used for croup and asthma attacks.
The multicenter study was published in the July 26 New England Journal of Medicine and conducted by the Pediatric Emergency Care Applied Research Network (PECARN).
It was highlighted that simply supportive care is the most effective option for bronchiolitis though steroid-based medications still play an important role in respiratory illnesses of childhood such as asthma and croup.
βarrestin2, a protein used for the purpose of regulation of androgen receptors’ expression, can be a new focal point for staging and curing testosterone-fueled prostate cancer, as per medical College of Georgia researchers. The study findings were reported in Proceedings of the National Academy of Sciences Online Early Edition.
As per study’s corresponding author, Dr. Yehia Daaka, Distinguished Chair in Oncologic Pathology in the MCG School of Medicine, an increase in the number of androgen receptors was what considered to be behind the growth of prostate cancer progression in men with advanced disease.
With increased numbers of androgen receptors, prostate cancer can make use of the limited testosterone available after a diseased prostate gland is removed or after testosterone production is blocked by drug therapy. In fact, the increased number of androgen receptors may mutate so they can start feeding off other steroidsor even growth factors, Dr. Daaka says.
These wily skills help explain why cancer returns despite initially promising treatment results.
“It is clear that signaling by the androgen receptor is paramount for not only the initiation but also the progression of the disease, including escape to a hormone-refractory disease,” he says. Moves androgen receptors make to support cancer growth make it “unbeatable at this point,” for some patients.
However increased levels of βarrestin2 appear to halt the potentially deadly increase in androgen receptor expression, the MCG research team has found.
Dr. Daaka, a Georgia Cancer Coalition Distinguished Cancer Scholar, remarked that initiation and progression of prostate cancer can be regulated by regulated by expression or non-expression of activation or repression of the androgen receptors’ co-factors.
The involved collaborators included Dr. Vijayabaskar Lakshmikanthan, postdoctoral fellow; Dr. Lin Zou, former postdoctoral fellow; Jae Kim, graduate student; Dr. Nidia C. Messias, assistant professor; and Dr. Zhongzhen Nie, assistant professor; from the MCG Department of Pathology; and Drs. Allison Michal and Jeffrey L. Benovic from Thomas Jefferson University.
The game of baseball has been kept under dark clouds after Mark McGwire made a belated confession of steroid use amidst crocodile tears and disclaimers. But Bud Selig thinks that the baseball steroid era is now over, a fact suggested by test results.
The use of Avastin alone can be considered as an effective form of treatment when it comes to treating a subgroup of recurrent Grade 3 brain tumors in terms of delaying tumor progression, as per a retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance.
Individuals suffering from mild, persistent asthma and being administered with twice-daily use of inhaled 
Bodybuilders and strength athletes making use of anabolic 
Surgical repair of massive or recurrent tears of the shoulder’s rotator cuff tendons can be improved with anabolic steroids, as per a research from the UNC’s School of Medicine.
A potential new treatment approach has been identified for treating severe asthma, as per a small study. The approach is focused up on blocking of a powerful immune system, which is present in large amounts in patients with the severe form of asthma.
Injecting a corticosteroid, triamcinolone, directly into the eye may slow the progression of proliferative diabetic retinopathy that is a complication of diabetes that results in blindness, according to researchers led by specialists at the Johns Hopkins Wilmer Eye Institute.
There is a possible link between a specific genetic variation and an increased risk for severe premenstrual depression, as per scientists at the 
βarrestin2, a protein used for the purpose of regulation of androgen receptors’ expression, can be a new focal point for staging and curing testosterone-fueled prostate cancer, as per 